MedPath

Siddha drug veppampoo Mathirai for Blood pressure

Phase 2
Not yet recruiting
Conditions
Diseases of the circulatory system,
Registration Number
CTRI/2022/02/040005
Lead Sponsor
Self
Brief Summary

This is an open clinical interventional evaluation of Siddha drug Veppampoo Mathirai for Systemic Hypertension. Both gender of age 18-60 will be enrolled based on inclusion and exclusion criteria. Intervention will be given for 60 days and the outcome is assessed on the basis of systolic, diastolic and mean arterial pressure before and after treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
31
Inclusion Criteria

Newly diagnosed systemic Hypertension patients having blood pressure value systolic 140-179mmHg and diastolic 90-109mmHg, willing to give written consent to participate in the study.

Exclusion Criteria

Blood pressure value having systolic greater or equal to 180mmHg and diastolic greater or equal to 110mmHg, Secondary hypertension, Diabetes mellitus, cardiovascular disease/ hepatic disease, asthmatic and copd patients, pregnant women and lactating mothers, patients who are on steroids, oral contraceptive pills, oestrogen replacement therapy.participants will be excluded clinically or based on available medical reports.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Outcome assessed by an expected reduction in blood pressure value of systolic 10-20mmHg and diastolic 5-15mmHg.0 day and 61 day
Secondary Outcome Measures
NameTimeMethod
Liver and renal parameters compared before and after treatment.0 day and 61 day

Trial Locations

Locations (1)

Aringnar Anna Government hospital of Indian medicine

🇮🇳

Chennai, TAMIL NADU, India

Aringnar Anna Government hospital of Indian medicine
🇮🇳Chennai, TAMIL NADU, India
S M Chitra
Principal investigator
09444177230
chittu758@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.